Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 7INDUSTRY 4NIH 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Endocrine 2Sarcoma 1Other solid neoplasm 1NET 1Genitourinary 1

Conditions

Sarcoma, Alveolar Soft Part 1Neuroendocrine Tumors 1Metastatic Neuroendocrine Prostate Cancer 1Chondrosarcoma 1Advanced Solid Tumors 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Antiemetics × Clear all
NCT06242691 2026-06-05

MK-1200-002

Merck Sharp & Dohme LLC

Phase 1/2 Completed
13 enrolled 21 charts
Other solid neoplasm

Advanced Solid Tumors

NCT06379217 2026-06-03

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Novartis

Phase 1 Active not recruiting
31 enrolled
EndocrineGenitourinary

Metastatic Neuroendocrine Prostate Cancer

NCT02592707 2023-07-19

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

Ipsen

Phase 1/2 Terminated
40 enrolled 37 charts
EndocrineNET

Neuroendocrine Tumors

NCT00401388 2018-03-07

A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas

AEterna Zentaris

Phase 2 Completed
72 enrolled
Sarcoma

Chondrosarcoma, Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡